A randomized, double-blind phaseIII trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy
Gonzalez, A., Moore, K.N., Mirza, M.R., Vergote, I.B., Pothuri, B., Oza, A.M., Graybill, W.A., Yalcin, I., Agarwal, S., Monk, B.J.Volume:
145
Language:
english
Journal:
Gynecologic Oncology
DOI:
10.1016/j.ygyno.2017.03.231
Date:
June, 2017
File:
PDF, 49 KB
english, 2017